Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.

MLA

Sra, Manraj Singh, et al. “Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.” JCO Global Oncology, vol. 10, July 2024, p. e2300433. EBSCOhost, https://doi.org/10.1200/GO.23.00433.

APA

Sra, M. S., Sasi, A., Batra, A., Bakhshi, S., & Ganguly, S. (2024). Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective. JCO Global Oncology, 10, e2300433. https://doi.org/10.1200/GO.23.00433

Chicago

Sra, Manraj Singh, Archana Sasi, Atul Batra, Sameer Bakhshi, and Shuvadeep Ganguly. 2024. “Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.” JCO Global Oncology 10 (July): e2300433. doi:10.1200/GO.23.00433.